DSGN (Design Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)


DSGN Design Therapeutics Inc DSGN
33 GF Score
Price $15.65
! 2 Warning Signs
View Full Analysis

What is Design Therapeutics FCF Margin %?

Design Therapeutics DSGN +6.68% 33 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates DSGN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 951 Biotechnology companies, Design Therapeutics ranks worse than 105152.37% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Design Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-16.43 Mil. Design Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Design Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Design Therapeutics's current FCF Yield % is -5.54%.

The historical rank and industry rank for Design Therapeutics's FCF Margin % or its related term are showing as below:


DSGN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -82.65
* Ranked among companies with meaningful FCF Margin % only.

Design Therapeutics FCF Margin % Related Terms

Design Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Design Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Design Therapeutics FCF Margin % Chart

Design Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Design Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

DSGN vs SPRY, GERN, PHAT: FCF Margin % Comparison

For the Biotechnology subindustry, Design Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Design Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Design Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Design Therapeutics's FCF Margin % falls into.


DSGN
33GF Score
Design Therapeutics Inc DSGN
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Design Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Design Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-54.551/0
= %

Design Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-16.431/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Design Therapeutics (DSGN) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Design Therapeutics and its competitors. According to the industry distribution chart, Design Therapeutics ranks #999999 out of 951 companies in the Biotechnology industry.
Is Design Therapeutics' FCF Margin % too high?
Design Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Design Therapeutics ranks #999999 out of 951 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Design Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Design Therapeutics' FCF Margin % compare to SPRY and GERN?
According to the Biotechnology industry distribution chart, Design Therapeutics ranks #999999 out of 951 companies for FCF Margin %. This places Design Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Design Therapeutics and its competitors. Design Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Design Therapeutics stock overvalued right now?
Design Therapeutics (DSGN) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Design Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Design Therapeutics (DSGN), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Design Therapeutics Business Description

Address 6005 Hidden Valley Road, Suite 110, Carlsbad, CA, USA, 92011
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
33GF Score

Get the complete analysis for DSGN

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.65
Price